or
Bookmark and Share
1,5-diphenylpyrazole derivatives
   
Document Number
US Patent 6316485
Issued Date
November 13, 2001
Link
Inventors
Map
Abstract
A compound of the formula (I): ##STR1## wherein: R.sup.1 is chlorine, difluoromethyl, trifluoromethyl or cyano; and R.sup.2 is a group having the formula: ##STR2## wherein: X is halogen, cyano, nitro or amino; Y.sup.1 is lower alkyl or lower alkoxy; and Z is halogen; or a pharmaceutically acceptable salt thereof.
Drawing
1,5-diphenylpyrazole derivatives - US Patent 6316485 Drawing
Drawing from US Patent 6316485
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
14
Comments:
no comments yet
Published
November 13, 2001
Application Number
09/508,507
Filed
March 23, 2000
US Classification
514/406   548/375.1 548/377.1
Int'l Classification
C07D   231/14   (20060101)   C07D   231/16   (20060101)   C07D   231/00   (20060101)   C07D   231/12   (20060101)  
Priority Data
Sep 24, 1997 [AU] PO9414
USPTO Field of Search
548/375.1   548/377.1   514/406  
Related Patents
7544678 - Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) - Owned by The Trustees of Columbia University In the City of New York (New York, NY)

The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBP12.6 in a subject; to prevent exercise-induced sudden cardiac death in a subject; and to treat or prevent heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia in a subject. The present invention further provides methods for identifying an agent that enhances binding of RyR2 and FKBP12.6, and agents identified by these methods. Additionally, the present invention provides methods for identifying agents for use in treating or preventing heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia, and in preventing exercise-induced sudden cardiac death. Also provided are agents identified by such methods.

7393652 - Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) - Owned by The Trustees of Columbia University in the City of New York (New York, NY)

The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBP12.6 in a subject; to prevent exercise-induced sudden cardiac death in a subject; and to treat or prevent heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia in a subject. The present invention further provides methods for identifying an agent that enhances binding of RyR2 and FKBP12.6, and agents identified by these methods. Additionally, the present invention provides methods for identifying agents for use in treating or preventing heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia, and in preventing exercise-induced sudden cardiac death. Also provided are agents identified by such methods.

7312044 - Type 1 ryanodine receptor-based methods - Owned by The Trustees of Columbia University in the City of New York (New York, NY)

This invention provides methods of treating defective skeletal muscle function during heart failure and methods for identifying compounds useful in such treatments.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us